Showing results (121-130 of 211) with videos related to

Sort By:
Pageof 22
Cancer Medicine|April 6, 2019
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuationSimona Bernardi, Michele Malagola, Camilla Zanaglio, et al.
Hemasphere|February 26, 2026
Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosisBarbara Mora, Matteo Franchi, Ludovica Margotto, et al.
Plos One|July 19, 2019
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatmentAlessandra Trojani, Ester Pungolino, Alessandra Dal Molin, et al.
Oncotarget|March 28, 2018
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patientsMario Tiribelli, Massimiliano Bonifacio, Gianni Binotto, et al.
Frontiers in Oncology|December 22, 2018
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid LeukemiaSara Galimberti, Susanna Grassi, Claudia Baratè, et al.
Cell Death & Disease|June 30, 2022
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemiaMohammad Houshmand, Nicoletta Vitale, Francesca Orso, et al.
Cytometry. Part B, Clinical Cytometry|February 5, 2019
Flow Cytometry Assessment of CD26<sup>+</sup> Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid LeukemiaDonatella Raspadori, Paola Pacelli, Anna Sicuranza, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase MyelofibrosisFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
American Journal of Hematology|July 17, 2015
Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV studySilvia Mori, Elisabetta Vagge, Philipp le Coutre, et al.
International Journal of Cardiology|April 29, 2019
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary preventionGiovanni Caocci, Olga Mulas, Massimiliano Bonifacio, et al.
Pageof 22